Antibiotice celebrates 25 years since its listing on the Bucharest Stock Exchange


Antibiotice (ATB), one of the most important Romanian generic drug producers, celebrates 25 years since its listing on the Bucharest Stock Exchange (BVB). The company’s shares are traded on the Stock Exchange starting with April 16, 1997, under the symbol ATB, in the Premium category. With a rich history and experience in the production of generic drugs, spanning over 60 years, the development of the company is closely related to its path on BVB. In these 25 years as a listed company, its capitalization has increased more than 15 times, currently reaching a value of over RON 360 million.

“Antibiotice is a leading company in the Romanian pharmaceutical industry. Of the 67 years of activity of Antibiotice, 25 years are closely related to the company’s course on the Bucharest Stock Exchange. We are glad that we have on the stock exchange an issuer with such a rich history and experience and that operates in a vital field of activity for all of us. The health sector in our country is very well represented on the stock market and Antibiotice is an issuer with a significant role that aims to align with current trends such as the implementation of ESG criteria. Thus, Antibiotice is one of the listed companies with outstanding performance in terms of ESG reporting, as demonstrated by the ESG score received in the project launched by BVB earlier this year. Congratulations to the entire Antibiotice team for all the successes so far and I wish you every success in everything you accomplish from now on”, stated Adrian Tanase, CEO of the Bucharest Stock Exchange.

“The listing on the Bucharest Stock Exchange was an extraordinary thing because it meant Life for Antibiotice. Antibiotice is the largest local producer of medicines with Romanian capital with an impressive 67-year history. For 25 years, our journey has been linked to our presence on the local stock exchange. I can say with certainty that the Bucharest Stock Exchange was a forerunner of increasing the transparency and predictability of the Antibiotice company. Today, when we talk about the 25 years on the capital market of the Antibiotice company, we can say that it was an absolutely necessary stage and a success. As before, we aim to be ingenious and adapt to the requirements of our end consumers but also to those of our investors and capital market partners. The maturity of the team, our approach to act according to sustainable management plans and the strict observance of the operating procedures represent the guarantee of our sustainable development”, said Ioan Nani, General Manager at Antibiotice.

In the 25 years since the listing, the investors have made 310,000 transactions with ATB shares. Thus, from the moment of listing until April 15, 2022, over 900 million shares with a total trading value of over RON 595 million were performed.

Founded in 1955 in Iasi, Antibiotice is now, 67 years after its establishment, one of the most important Romanian producers of generic drugs, whose mission is to manufacture safe, effective and quality pharmaceutical products to give patients hope for a healthy life. Since 1955, when it produced on an industrial scale the first antibiotic in Romania - the active substance Penicillin, the Antibiotice company has developed its production platform, so that now it has the most complex manufacturing structure in Romania, with 8 distinct production flows, which one, unique in the country, is intended for obtaining active substances through biosynthetic processes. Over time, through its own research, Antibiotice has produced a diverse range of generic drugs, reaching a portfolio of over 150 finished drugs in 11 therapeutic classes (anti-infective, cardiovascular, dermatological, digestive, central nervous system, etc.).

Antibiotice has an active global presence and exports its products to all continents, managing to make valuable medicines more accessible to patients, both in Romania and in over 70 countries around the world.